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PREFACE 
I began my career in healthcare over twenty years ago, with the last fourteen 
in the field of oncology.  While I’m not a clinician, the disease is multifaceted and is 
constantly evolving.  Today, in 2019, we are seeing breakthroughs in which one drug 
can treat different types of cancer.  I foresee over the next 20 years, cancer will not 
be cured, but I am confident many cancers will be managed as a chronic disease, 
giving survivors not a death sentence but an opportunity to experience a fulfilled 
quality of life.  This has already been demonstrated in certain breast cancers as well 
as prostate, colon, and lung.  Patients are experiencing remission within these cancer 
indications due to standard of care practices associated with annual screenings, public 
health organizations promoting methods to reduce exposures to the disease, as well 
as through outcomes from clinical research.  When I first considered the topic for my 
dissertation, I knew it would be directed in cancer.  I was led to ovarian cancer by 
reading the literature and hearing about patient stories, where many are diagnosed at 
such a late stage.  No annual or effective screening is available, and more importantly, 
as the patient population is relatively small, commercializing a multi-million dollar 
therapy is cost prohibitive.  When I came across Dr. Goff’s research efforts associated 
with symptoms and further discussed my thoughts around this project with advisors, 
Drs. Krause and Cazaban, it became clear that evaluating symptoms in commercial 
claims would be relevant to this field and the findings could potentially contribute to 
detecting this disease at an earlier stage, receiving treatment before the cancer has 
spread.   
Acknowledgements 
To complete my doctorate has been a journey for me.  I was very fortunate to have a 
supportive committee who was committed to my research.  Additionally, I could not 
have gotten to this final stage of the program without my parents, my wonderful 
friends, my colleagues at The University of Texas MD Anderson Cancer Center, my 
advisors, and Lopita Gosh, and Youngren Kim, all of whom have encouraged and 
supported me.  Collectively, all have contributed to this research whether in asking 
questions, listening, allocating their time, or assisting me with Stata codes.  I will 
always be grateful.      
A RETROSPECTIVE ANALYSIS OF CLAIMS DATA TO DETERMINE SYMPTOMS 
ASSOCIATED WITH OVARIAN CANCER  
Denise Manon Langabeer MBA, MPA, PhD 
The University of Texas  
School of Public Health, 2019 
Dissertation Chair: Trudy Millard Krause, DrPH 
According to the American Cancer Society, approximately twenty percent 
(20% of women with ovarian cancer are diagnosed at an early stage (e.g. stage I or 
II), which subsequently means eighty percent (80%) of women diagnosed with this 
disease are at the late stage (e.g. stage III or IV) and are likely not to survive.  No cure 
exists and, concurrently, studies show mixed results in utilizing blood tests and 
transvaginal ultrasounds to screen for ovarian cancer.  While symptoms are not easily 
discernable, some oncologists have validated there are common symptoms women 
experience prior to diagnosis.  As these symptoms are not routinely recognized by 
general practitioners as an indicator to detect ovarian cancer, we conducted a 
retrospective study to determine whether certain types of symptoms are evident prior 
to the diagnosis.  Our two specific aims included:  (1) conduct an exploratory study to 
determine if certain symptoms were prevalent in women that are diagnosed with 
ovarian cancer; and (2) assess and compare symptoms experienced by women 
diagnosed with ovarian cancer to women that have not been diagnosed with any type 
of cancer.  The symptoms were identified by forty-seven (47) International 
Classification of Disease, 9th revision (ICD-9), diagnosis codes and categorized into 
four primary groups: (i) abdominal-pelvis; (ii) bladder; (iii) digestive; and (iv) pain.  In 
conjunction with identifying the type of symptoms experienced, reoccurrence and 
combination of symptoms were also analyzed.  The data to support this study was 
derived from health insurance claims between 2008 through 2013 from a commercial 
payer.  All subjects for both studies were residents in the state of Texas and were a 
minimum of 24 years old.   
The analysis of the first aim of the study was primarily descriptive to assess 
symptoms and frequencies experienced prior to diagnosis.  Of the 3,601 women 
diagnosed with ovarian cancer, 2,292 (64%) experienced a related symptom prior to 
or at diagnosis. Over 60% (n=1544) of women experienced a first symptom associated 
with abdomen and pelvis and 85% of overall complaints were associated with this 
group of symptoms.  Pain was the second most frequent complaint at 45%, followed 
by digestive at 24% and bladder at 18%.  This was also confirmed in women who 
experienced a combination of symptoms where abdomen and pelvis along with pain 
was shown to be the highest complaint at 41%.     
The results of the first study consequently led to pursue the second aim which 
included a nested case control study comparing a subset of 789 women diagnosed 
with ovarian cancer to women who did not have any history of cancer.  The results 
supported statistical significance in symptoms experienced specific to abdomen and 
pelvis in conjunction with pain as well as digestive.   
While these symptoms are ordinary and are difficult to distinguish as having an 
association with ovarian cancer, the findings of this research appear to affirm that a 
symptom index may prove to be a useful method when recurring complaints are 
presented in women.     
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Background & Literature Review 
Ovarian Cancer  
Worldwide over 200,000 women are diagnosed with ovarian cancer and 
125,000 die on an annual basis (Sankaranarayanan R., 2006).  In the U.S., the 
National Cancer Institute estimates that 22,000 new women are diagnosed with this 
disease each year.  Nearly 50% of the diagnosed cases occur in women under the 
age of 65 and overall survival is generally less than 5 years (Ovarian Cancer, 2015).  
It accounts for three percent of cancers among women (Cancer, 2015).  While this 
may appear to be a low figure compared to other cancer mortalities, it unfortunately 
results in more deaths than any other oncologic disease of the reproductive system 
(Cancer, 2015).    Ovarian cancer begins in the ovaries and is distinguished by three 
different types of tumors:  a) Epithelial, b) Germ Cell, and c) Stromal.  Epithelial is the 
most common type of ovarian cancer, representing 85%-90% of all cases (Cancer, 
2015).   
This cancer is recognized as an asymptomatic disease and thus is identified as 
a “silent killer” (Goff B. A., 2007).  Unlike other cancers, such as breast, lung, cervical, 
prostate, colon or skin, no standard screening requirements to evaluate the risk of 
ovarian cancer are supported by professional organizations such as The American 
Congress of Obstetricians and Gynecologists or the United States Preventative 
Services Task Force (USPSTF).  While studies show mixed results in utilizing blood 
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test and transvaginal ultrasounds to diagnose ovarian cancer, leading gynecological 
experts, such as Dr. Barbara Goff, have validated there are common symptoms 
women experience prior to diagnosis.   These symptoms are not recognized routinely 
within clinical practice to detect ovarian cancer and subsequently this may lead to 
women being misdiagnosed, causing the disease to advance to a later stage.  
Continued research is necessary to further assess if recurring symptoms are shown 
to have an association to ovarian cancer and, if so, whether these symptoms can be 
applied as part of standard of care practice, offering earlier diagnosis, and 
subsequently leading to earlier treatment and possibly long-term survival.   
Symptoms of Ovarian Cancer  
  Ovarian cancer is difficult to diagnose and when it is discovered, many women 
are at such an advanced stage of the disease that the therapy is provided for palliative 
reasons.  The survival rate is highly dependent on whether the cancer has spread to 
other organs, the woman’s age, and response to treatment (NCI, 2015).   If the disease 
is confined to the ovary, also known as Stage 1 (localized), five year survival rates can 
range between 70% and 90% (Cannistra, 2004; NCI, 2015).    Once the disease 
advances beyond Stage I or Stage II, the average five year survival rate begins to 
diminish as the cancer has either spread beyond the pelvis and has potentially 
penetrated the lymph nodes (regional) or metastasized (distant) into other organs.  
The National Cancer Institute’s SEER data suggests that between 2005 and 2011,  
sixty percent (60%) of women are diagnosed as “distant” and a mere fifteen percent 
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(15%) are “localized” (NCI, 2015), further affirming that prognosis of this disease is 
not only dismal, but also requires research to assess opportunities to detect this 
disease as early as possible (Figure 1).    
Figure 1:  5-Year Relative Survival  
SEER 18 2005-2011, All Races, Females by SEER Summary Stage 2000  
  
 Symptom management of this disease has been limited. In the 1970s, a study 
of over 5,000 women showed that most patients with ovarian cancer experienced 
symptoms anywhere from two weeks to ten years prior to diagnosis (Ranney, 1979).   
This research subsequently has paved the framework for Dr. Barbara Goff, an 
oncological gynecologist and leading expert in ovarian cancer.  Her studies in the last 
10 years reveal that common targeted symptoms are evident between six and twenty-
four months prior to diagnosis (Goff B. A., 2007) (Goff B. M., 2004).  As a result of her 
research, clinicians now are beginning to recognize common ailments in women that 
require further investigation.    
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 Several related symptoms addressed in Dr. Goff’s research, otherwise known 
as the “symptom index” set the basis on what other investigators use as part of their 
methodological framework when evaluating symptoms associated with ovarian 
cancer.   The categories to support these symptoms include areas associated with 
pain, eating, abdomen, bladder, bowels, menses, intercourse, and other (Goff B. M., 
2004).   The symptom index is shown to be positive if one or more symptoms occur 
for less than one year but for more than 12 days per month (Goff B. A., 2007).   
Screening 
 Today, there are several types of screening tests that have shown to identify 
the risk of breast, lung, cervical, prostate, colon, and skin cancer.  These screening 
tests are endorsed by national organizations such as the U.S. Preventive Services 
Task Force, American Cancer Society, and American Society of Clinical Oncology and 
are recognized as standard of care procedures by payers and clinicians.  In contrast, 
there are no standard of care screening methods for ovarian cancer.  Over sixty 
percent (60%) of ovarian cancer cases are found at Stage III and IV (Clarke-Pearson, 
2009), which ultimately impacts a woman’s survival rate, as the cancer has more than 
likely spread to other organs, making it very difficult to treat and place the cancer into 
remission.   
 Should a physician detect that a woman is at risk of the disease, there are two 
procedures that are initially performed prior to performing surgery to confirm 
diagnosis.  One is the transvaginal ultrasonography and the other is a blood test 
known as a CA-125.  While both procedures are noninvasive and can offer some 
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indication if a woman may or may not have ovarian cancer, the specificity and 
sensitivity of these tests remain questionable on whether early detection (e.g. Stage 
I) can be determined, thus potentially leading to needless surgeries (Clarke-Pearson, 
2009) . 
Importance of Earlier Diagnosis  
While routine screening methods are not endorsed as standard of care, studies 
show women that are detected at an early stage (e.g. Stage I) are able to experience 
five year survival rates as high as 90%.  This is primarily because the cancer has not 
spread outside of the ovary.  Unfortunately, though, only a small percentage of women 
are diagnosed at this stage.  Therapeutic options in this disease are beginning to 
evolve, especially in the field of personalized medicine (i.e. use of genetic profiles in 
the treatment of cancer), but effective screening, early detection, and cure remain 
obscure (Rauh-Hain, 2011).  For women to benefit from the chemotherapies and 
simultaneously improve their survival rates, some form of early detection is needed.  
Although screening tests are not routinely performed, oncologists, such as Dr. Goff, 
are attempting to implement clinical decision strategies by incorporating a symptom 
index that will enable physicians to possibly identify whether their patient is at risk of 
the disease.  If the symptoms are evident, then further diagnostic tests can be 
pursued.    
Public Health Significance 
Ovarian cancer remains a lethal disease world-wide.  While the overall 
prevalence is much smaller compared to breast and lung cancer, the long-term 
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survival rates are one of the worst where 10-year survival is expected to be less than 
50%.  The main areas that influence the current state of why women are not currently 
screened as well as why symptoms are not recognized as indicators in this disease 
include patient awareness, the ordinariness of the symptoms, and current clinical 
practice.  Patient awareness is affected by the lack of information and knowledge in 
recognizing that certain patterns could be associated with signs of ovarian cancer.   
Target symptoms as distinguished in the literature by experts such as Dr. 
Barbara Goff and others remains in question by clinicians and organizations such as 
the Centers of Medicare and Medicaid, U.S. Preventative Task Force, American 
Congress of Obstetricians and Gynecologists, and American Society of Clinical 
Oncology.  In addition to the lack of both patient awareness and understanding of 
target symptoms, clinicians, in general, do not appear to be familiar with symptoms 
that are evident in this field of medicine.  Unless a physician is trained as an oncologist, 
the primary care physician or gynecologist is generally not leaning towards cancer as 
the initial diagnosis.  The combination of the patient, the healthcare industry, and the 
clinicians collectively not recognizing the correlation of the symptoms to ovarian 
cancer may lead to delays in earlier diagnosis as well as treatment. The proposed 
research objectives have the potential to contribute to a better understanding of 
symptom indicators that may be associated with the disease, offering further 
awareness.   
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This research is intended to explore whether symptoms are evident in women 
diagnosed with this disease, and if so, how long and how frequent did the symptoms 
occur prior to diagnosis.   
Specific Aims 
The main objective of this research is to determine if there is an association of 
certain symptoms women experience prior to the diagnosis of ovarian cancer.  
Outlined below are the primary research questions and related aims for this research: 
Research Question 1: What are the frequencies and types of symptoms prior to 
diagnosis of ovarian cancer?  
Aim 1:  To evaluate and compare whether certain symptoms exist prior to diagnosis 
in claims data.  Primary symptoms include bloating, increased abdominal size, 
abdominal pain, pelvic pain, difficulty eating, feeling full quickly and the frequency 
(Andersen, 2014).   
Research Question 2:  What is the frequency and type of the symptoms prior to 
diagnosis in comparison to an aged-matched control group of women who are not 
diagnosed with cancer?  
Aim 2:  To determine whether women diagnosed with ovarian cancer indicate a 
different frequency of target symptoms than the aged-match control group.  
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Overview of Methods 
Study Design:  Both studies involved a retrospective analysis of insurance claims 
over a five year period.  Symptoms for both study aims were identified based on 47 
International Classification of Disease (ICD-9) codes specific to pain, abdominal and 
pelvis, digestive, and bladder.  The first study aim (1st Journal Article) was exploratory 
and descriptive, evaluating symptom complaints prior to diagnosis.  The second study 
aim (2nd Journal Article) supported a nested case control study, which included a 
cohort of women diagnosed with ovarian cancer and were randomly matched to 
women who had no history of cancer.  The second aim would compare type of 
symptom complaints and frequencies experienced by women with ovarian cancer to 
women with no history of cancer.   
Study Subjects:  Subjects were identified as women diagnosed with ovarian cancer 
(both studies) and women with no history of cancer (second study aim only).   
Sample Size:   
Study Aim 1 (1st Journal Article)  
o Women diagnosed with ovarian cancer n= 3601  
Study Aim 2 (2nd Journal Article)  
 
o Women diagnosed with ovarian cancer n=789  
o Women with no history of cancer n=789  
o Total sample size n = 1578 
Data Collection:  Extraction of claims and related member files (inclusive of date of 
birth) were based on: a) women diagnosed with ovarian cancer based on ICD-9 
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diagnosis codes 183.x, malignant neoplasm of ovary, and 233.39, carcinoma in situ 
of the ovary), b) women with no history of cancer based on the exclusion of any history 
of cancer based on ICD-9 diagnosis codes of 140.x through 239.x; and lastly c) 
included all visits (claims) within the observation period.   
Data Analysis:  Analysis for the first study aim (1st Journal Article) was exploratory 
and descriptive;  Analysis for the second study aim (2st Journal Article) was descriptive 
and odds ratios and p values were determined based on conditional logistic 
regression.   
Human Subjects, Animal Subjects, or Safety Considerations:  No human or 
animal subjects were involved in these studies.  This study was approved by the 
Institutional Review Board of The University of Texas – School of Public Health.   
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Journal Article (1st) 
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Are Certain Types of Symptoms Experienced Prior to the Diagnosis of Ovarian 
Cancer?   
AUTHORS:  Denise Manon Langabeer1, Cecilia Ganduglia Cazaban2, Michael D 
Swartz2, David Lopez2, and Trudy Millard Krause2 
1The University of Texas MD Anderson Cancer Center, Houston, Texas   2The 
University of Texas School of Public Health, Houston, Texas 
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ABSTRACT (236 words) 
Are Symptoms Experienced Prior to the Diagnosis of Ovarian Cancer?  A 
Retrospective Study of Insurance Claims Over a Five-Year Period 
 
Denise Manon Langabeer, Cecilia Ganduglia Cazaban, Michael D Swartz, David 
Lopez, Trudy Krause; The University of Texas MD Anderson Cancer Center, 
Houston, TX; The University of Texas School of Public Health, Houston, TX 
 
Abstract Text: 
 
Background:  The US healthcare system does not support a standard screening 
method for ovarian cancer, a disease where over 60% of ovarian cancer cases are 
found at a late stage.  The purpose of this study is to determine whether certain types 
of symptoms are evident prior to the diagnosis.  Methods:  A retrospective analysis 
of health insurance claims between 2008 through 2013 from a commercial payer 
based on the following eligibility criteria: 1) women diagnosed with ovarian cancer, 2) 
at the time of diagnosis, 24 years of age or older, 3) continuously enrolled in healthcare 
plan for a minimum of 6 months prior to diagnosis, and 4) a Texas resident.  Symptoms 
were based on 47 ICD-9 diagnosis codes and categorized specific to pain, abdominal 
and pelvis, digestive, and bladder. Results:  Of the 3,601 of women diagnosed with 
ovarian cancer, 2,292 (64%) experienced a related symptom prior to or at diagnosis. 
Over 60% (n=1380) of women experienced symptoms associated with abdomen and 
pelvis.  Over twelve hundred women age 30 and over 65 experienced a first symptom 
greater than 90 days prior to diagnosis, with the number of unique visits ranging from 
1 to 41 per woman.  A combination of symptoms occurred in over 50% of women 
(n=1230).  Conclusions:  Of the 3,601 women diagnosed with ovarian cancer, the 
majority experienced symptoms prior to diagnosis.  Complaints specific to abdomen 
and pelvis appear to be the most common across all age groups. 
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INTRODUCTION 
While cancer research is producing remarkable outcomes in the field of 
oncology, ovarian cancer remains a disease with short-term survival.  Worldwide, over 
200,000 women are diagnosed with this disease and 125,000 die on an annual basis1.  
In the U.S., the National Cancer Institute estimates that over 22,000 new cases occur 
annually and 14,070 women die due to this cancer2. Nearly 50% of the diagnosed 
cases occur in women under the age of 65 and overall survival is generally less than 
5 years3.  It accounts for three percent of cancers among women4.  While this statistic 
may appear to be insignificant compared to other cancers, it results in more deaths 
than any other oncologic disease of the reproductive system4.       
Ovarian cancer is recognized as an asymptomatic disease5.  The survival rate 
is highly dependent on whether the cancer has spread to other organs, the woman’s 
age, race, and response to treatment6.  Unlike other cancers, such as breast, lung, 
cervical, prostate, colon or skin, no standard screening requirements to evaluate the 
potential risk are supported by professional organizations such as The American 
Congress of Obstetricians and Gynecologists or the United States Preventative 
Services Task Force (USPSTF).  In January 2018, the Journal of American Medical 
Association published USPSTF’s decision that screening for ovarian cancer in 
asymptomatic women by performing a blood test, known as the cancer antigen 125 
(CA-125), or the use of transvaginal ultrasounds are not beneficial, cost effective, and 
do not provide opportunities for an early diagnosis7.  The USPSTF has taken this 
position as a result of recent research that has shown that these screening methods 
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are inconsistent leading to false positives or unremarkable findings.  This was 
corroborated by the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian 
(PLCO) Cancer Screening Randomized Controlled Trial, where nearly 80,000 women 
were randomized to either obtain annual screening tests using both the CA-125 and 
the transvaginal ultrasound or proceed with usual care.  For women randomized to 
annual ovarian cancer screening methods, more than 25,000 women were screened 
utilizing both tests in the first three years of the study, and then subsequently with CA-
125 for a period of two years.  In total, 6 annual CA-125 tests and 4 annual 
transvaginal ultrasounds were performed on each women involved in the study8.  The 
investigators of the PLCO study followed the women for over 12 years and determined 
there was no statistically significant reduction in mortality in ovarian cancer between 
the women that were tested annually versus women who received usual care8.   
Today, innovative therapies are being offered to treat cancer in several 
indications (e.g. breast, lung, skin and liver).  However, it remains a challenge to direct 
an effective clinical treatment to the ovarian cancer population that leads to long-term 
survival.  The inability to diagnose at an early stage and inadequate therapies are two 
primary reasons this disease is extremely difficult to prevent or cure. Nearly 85% of 
women will be diagnosed when the cancer has spread or metastasized outside of the 
ovary, which sadly leads to a premature death2. A component of this research is to 
continue to stimulate awareness of the possible enduring symptoms that recur in 
ovarian cancer.  
17 
 
When symptoms tend to be ambiguous, time, inadvertently, is used as a 
diagnostic tool.  Without an effective screening strategy to determine early detection 
of ovarian cancer, symptom research needs to continue and be part of a holistic 
approach that is inclusive of a diagnostic pathway.  Symptom research has been 
monitored in this disease for several decades.  In the 1970s, a study of over 5,000 
women showed that most patients with ovarian cancer experienced symptoms 
anywhere from two weeks to ten years prior to diagnosis9. Other later clinical research 
revealed that common targeted symptoms are evident between six and twenty-four 
months prior to diagnosis5, 10.  Goff et al established an ovarian cancer symptom index 
which has been used in several case-control studies11.  The index measures whether 
women experienced certain symptoms specific to pelvic/abdominal pain, difficulty 
eating, urinary urgency, and bloating prior to diagnosis. The reporting of symptoms in 
this disease appear to be an indicator to ovarian cancer.   
This study is a retrospective analysis of healthcare claims from a large U.S. 
commercial payer.  The primary aim of this research is to assess whether certain 
symptoms are apparent prior to the diagnosis of ovarian cancer.  The research is 
descriptive and will explore: a) the type of symptoms experienced, b) when the 
symptoms occurred, and c) how frequently women visited their provider. 
MATERIALS AND METHODS  
 This study was approved by the Institutional Review Board of The University of 
Texas – School of Public Health.  To support the study aim, a retrospective analysis 
of health insurance claims from a commercial payer between 2008 through 2013 was 
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performed.  A cohort of 4,406 women diagnosed with ovarian cancer was extracted 
from 3,596,696 unique women.  Inclusion criteria for the analysis were the following: 
a) women diagnosed with ovarian cancer (ICD-9 diagnosis codes: 183, malignant 
neoplasm of ovary, and 233.39, carcinoma in situ of the ovary); b) residentially lived 
in the state of Texas, c) enrolled continuously in the plan for a minimum of 6 months 
prior to diagnosis, d) equal to or greater than 24 years of age at diagnosis.  Of the 
4,406 women diagnosed with ovarian cancer, 805 women were dropped from the 
cohort due to:  a) diagnosis date was outside of the continuous enrollment periods; 
and b) diagnosis date before symptom date.  This resulted in 3,601 women diagnosed 
with ovarian cancer to be analyzed (Figure 1).   
Related symptoms were identified in the claims by 47 International 
Classification of Disease (ICD-9) codes specific to pain, abdominal and pelvis, 
digestive, and bladder (Table 1).  As the hypothesis supports a review of symptoms 
prior to diagnosis, any claims that occurred subsequent to the diagnosis date were 
dropped from the analysis.    Associated symptoms were analyzed by age group, 
number of visits (based on claims), time period, and combination of symptoms.   
   The dataset for the analysis was compiled by two separate data files based on 
the research criteria noted above.  The first dataset comprised of enrollees who met 
the demographic criteria specific to age, enrollment period, and residence.  The 
second dataset was based on member (n=3,601) claims specific to the cancer 
diagnosis and symptoms.    Once each dataset met the specifications, the datasets 
were matched based on member identification number and merged.     
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 The statistical package used for the analysis was STATA 13.1.   This research 
primarily reports descriptive analyses and includes the following:  i) proportions of the 
number of women that experienced a visit with symptoms versus no symptoms, ii) the 
type of first symptoms experienced prior to diagnosis, iii) the number of days the first 
symptom occurred prior to diagnosis, iv) combination of symptoms experienced, and 
v) the range of recurring visits by symptom and age.   
RESULTS  
 There were 3,601 women included in the analysis that met the study criteria.  
Women ranged in age from 24 through 89, with an average age of 53 (SD 12.20).  Of 
the 3,601 women, symptoms prior to the diagnosis were found in 64% (n=2292) 
(Figure 2).  Of the women that experienced symptoms prior to diagnosis, 32% (n=731) 
were between the age of 50 and 59.  The analysis further revealed that 60% of women 
treated for their first symptom primarily presented with a complaint associated with 
abdomen and pelvis.  The second most frequent complaint as a first symptom was 
associated with pain (16%), followed by digestive (13%), and bladder (11%) (Figure 
3).   
Of the 2,292 women with symptoms, time and the number of visits was 
reviewed.  The following results are described in figures 4 through 6.  To understand 
the time between first symptom and diagnosis, the researchers performed an analysis 
on the number of days the initial symptom occurred prior to the diagnosis.   Women 
that experienced a symptom on the day of diagnosis were removed from the analysis 
and further analysis occurred on symptoms that ranged between 1 to greater than 365 
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days.  Of the 2,292 women, 46% (n=1063) experienced a first symptom under 90 days 
prior to diagnosis.  Women in this analysis from age 30 to over 65 (n=739; 32%) had 
a first symptom visit over a year prior to diagnosis.     
In conjunction with determining the number of days of the first symptom prior 
to diagnosis, the number of symptom visits by each of the 2,292 women was analyzed.  
A total of 10,970 visits (correlated with date of service) across all age groups were 
evaluated.  Eighty-five percent (85%; n=1954) complained of symptoms associated 
with abdomen and pelvis with over 1,400 women experiencing more than one visit.   
Complaints associated with pain effected forty-five percent (45%; n=1031) of women, 
with digestive following at 24%, and bladder at 18% (Figure 4).   Plot graphs were 
created to show the distribution of visits for each category of symptoms by number of 
women.  Nearly 500 women experiencing symptoms for abdomen and pelvis went to 
their physician five or more times.  Four women had over 30 recurring visits in this 
symptom (Figure 5).  Each of the other category of symptoms also displayed a range 
of recurring visits.  Over 100 women had five or more recurring visits associated with 
digestive, with one experiencing forty-one (41) visits (Figure 6).  In regards to bladder, 
these symptoms appear to be less frequent than the other symptoms, however, 138 
women did experience between two to eighteen recurring visits (Figure 7).  Lastly, 
symptoms associated with pain ranged between 2 visits to 41, with seventy-two 
women experiencing five or greater (Figure 8).    
Another segment to the analysis involved whether women may have 
experienced a combination of symptoms.  Of the 2,292 women, 54% (n=1,230) 
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experienced a combination of symptoms prior to diagnosis.  A total of ten different 
combinations were analyzed.  The results showed that 41% experienced symptoms 
associated with pain along with abdomen and pelvis, and 17% experienced digestive 
with abdomen and pelvis (Figure 9; Table 2).  Combination of symptoms were 
experienced in all age groups, with 53% in women aged 40 to 59.      
DISCUSSION  
This research remains relevant as ovarian cancer continues to be recognized 
as a disease where long-term survival statistics are dismal.  Currently, the female 
gender comprises of nearly 50% of the world population and life expectancy is 
expected to grow as a result of public health advances, which in turn is also projected 
to lead to an increase of cancers cases of nearly 10 million with 5.5 million deaths by 
203012.   Agencies such as the National Cancer Institute, American Cancer Society, 
and other noteworthy coalitions assert that 50% of ovarian cancer cases occur under 
the age of 65, with the median age of 63.  This statistic was further supported by the 
commercial claims data used for this research, where 80% of the 3,601 women 
diagnosed with this disease were between the ages of 30 through 64 (n=2895).  This 
research shows that pre-existing symptoms, especially specific to abdomen and 
pelvis, appear to exist prior to diagnosis.  Of the initial 3,601 women, 64% experienced 
a related symptom prior to or on the day of diagnosis.  Further analysis of the 2,292 
women that experienced a symptom, 54% (n=1233) had a first visit between 91 days 
to over a year prior to diagnosis.  The frequency of symptom visits ranged from 1 to 
more than 40 visits.    
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The investigators recognize that this type of prescreening assessment cannot 
independently lead to a diagnosis of ovarian cancer.  However, this study does 
strongly suggest that a taxonomy of symptoms is beneficial as a prescreening 
approach prior to pursuing tests, such as a CA125 or transvaginal, which can be 
expensive and also lead to false positives13.  With most hospitals both in the U.S. and 
abroad utilizing sophisticated electronic health records and big data analytics (e.g. 
IBM Watson), evaluation of symptoms in combination with a thorough risk assessment 
could lead to opportunities for better clinical decisions as well as offering earlier 
interventions.  While not extensively shown in ovarian cancer thus far, there is 
research that is demonstrating impactful results in other areas.  For example, in 
diabetic retinopathy, the investigators applied a clinical decision support system 
(CDSS) in conjunction with a lab data and patient demographics to detect 
susceptibility to diabetic retinopathy (DR) with high accuracy14.  Similar to ovarian 
cancer, detection of DR is asymptomatic and requires specialized physicians (i.e. 
ophthalmologists) and expensive tests to assess the risk.  The researchers of the 
study were able to develop a predictive clinical application that could accurately detect 
DR at 93% based on a routine blood test14.   
Limitations and Strengths 
Insurance claims were historically developed for the purpose to support 
physician documentation and charge reimbursement, which for purposes of research, 
such as the one presented, has limitations.  For example, for this study, detailed 
clinical information about the disease, demographics, and stage of the disease are not 
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captured in the claims data.  Additionally, the claims associated with this study are 
from a commercial payer, which eliminates any data from women who may be on 
primary healthcare plans associated with the Centers for Medicare and Medicaid 
Services.  This limits extrapolation of our findings to other populations such as 
uninsured and lower income women as well as women over the age of 65.    
 Apart from the limitations of the analysis, this research exhibits strengths.  The 
database used for this study has over 3.5 million women members in the state of 
Texas, and enabled the investigators to analyze age, time of symptoms to diagnosis, 
number of visits specific to related symptoms, as well as combination of symptoms 
without recall bias.  Another advantage of using claims data is the ability to evaluate 
visits across multiple providers. 
CONCLUSIONS 
Patients routinely experiencing a type of symptom epidemiology want to be 
referred and diagnosed expeditiously15.  While meaningful advancements continue to 
rapidly evolve in diagnostics and genetic testing, ovarian cancer still remains without 
any type of standard screening method along with limited treatment options.  It is 
inferred that early detection increases the chances for long-term survival.  This 
research supported that over 64% women experienced a related symptom, with the 
majority experiencing recurring symptoms.   
Incorporating a symptomology index as part of the clinical diagnostic strategy 
may lead to earlier detection16.   Although the results were not statistically significant, 
a recent United Kingdom Collaborative Trial of Ovarian Cancer Screening revealed a 
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15% reduction in ovarian cancer mortality with multimodal screening which included 
a CA125 based risk of ovarian cancer algorithm (known as ROCA) followed by 
transvaginal ultrasound, if the ROCA was abnormal17.  Based on the outcomes of our 
exploratory retrospective analysis as well as other studies, including prospective 
clinical studies such as those supported by Dr. Goff, it does appear that more 
awareness needs to be directed to women and health care providers.  In the United 
States, the National Cancer Institute is disclosing some early results of a NCI-funded 
study of an experimental pap screening test.  The retrospective study detected 
endometrial and ovarian cancer through DNA collected from blood and tissue2.  
Further research needs to continue, both within the U.S. and globally, to not only 
validate the efficacy of symptoms related to ovarian cancer, but also whether recurring 
symptoms are red flags to subsequently promote diagnostic testing whether through 
traditional methods (i.e. CA-125 blood test, transvaginal ultrasound) or more 
advanced methods such as molecular pathways evaluating the cytology of the human 
cells.  
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Figure 1 Study Design 
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Table 1 Symptoms Categorized by ICD9 Diagnosis Codes (47 codes  
 
Category  ICD9  Description                 Pain  6250  Dyspareunia                      
   6255  Pelvic congestion syndrome                   
   6258  Other specified symptoms associated with female genital organs       
   6259  Unspecified specified symptoms associated with female genital organs       
   7245  Backache                      
Abdomen & 
Pelvis  5340  Gastritis                          
   5781  Blood in stool                      
   6262  Excessive or frequent menstruation                
   6266  Metrorrhagia; bleeding unrelated to menstrual cycle; irregular intermenstrual bleeding 
   6267  Postcoital bleeding; bleeding from vagina after sexual intercourse       
   6268  Dysfunctional or functional uterine hemorrhage              
   6269  Disorders of menstruation & other abnormal bleeding from female genital tract; unspecified 
   7890  Abdominal pain                      
   78900  Abdominal pain; unspecified                   
   78901  Abdominal pain; right upper quadrant                
   78902  Abdominal pain; left upper quadrant                
   78903  Abdominal pain; right lower quadrant                
   78904  Abdominal pain; left lower quadrant                
   78905  Abdominal pain; periumbilic                   
   78906  Abdominal pain; epigastric                   
   78907  Abdominal pain; generalized                   
   78909  Abdominal pain; other specified site                
   7893  Abdominal or pelvic swelling, mass or lump             
   78930  Abdominal or pelvic swelling, mass or lump; unspecified          
   78935  Abdominal or pelvic swelling, mass or lump; periumbilic          
   78936  Abdominal or pelvic swelling, mass or lump; epigastric          
   78959  Ascites ‐ fluid in peritoneal cavity; other specified site          
   7896  Abdominal tenderness                   
   78965  Abdominal tenderness; periumbilic                
               
   78966  Abdominal tenderness; epigastric                
   78960  Abdominal tenderness; unspecified                
   7899  Other symptoms involving abdomen and pelvis             
Digestive  5361  Acute dilatation of stomach                   
   5369  Unspecified functional disorder of stomach             
   7830  Anorexia (loss of appetite)                   
   7831  Abnormal weight gain                   
   7832  Abnormal weight loss                   
   7873  Flatulence, eructation & gas pain                
   7879  Other symptoms involving digestive system             
   78791  Diarrhea                         
Bladder  7880  Renal colic                      
   7881  Dysuria                         
   7883  Urinary incontinence                   
   78840  Frequency of urination & polyuria                
   78841  Urinary frequency                      
   78842  Polyuria                         
   78843  Nocturia                         
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Figure 2  Women with Symptoms and No Symptoms  
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Figure 3  First Symptoms 
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Figure 4 Number of Women Experiencing Recurring Symptoms  
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Figure 5 Frequency of Visits by Women for Each Symptom (Abdomen and 
Pelvis) 
 
 
 
 
 
 
 
 
  Visits Women
0 338 ********************************
1 554 *****************************************************
2 421 ****************************************
3 290 ****************************
4 196 *******************
5 146 **************
6 109 **********
7 67 ******
8 42 ****
9 33 ***
10 18 **
11 16 **
12 13 *
13 15 *
14 5
15 6 * 85% of women had abdom & pelvis symptoms
16 3
17 3
18 1
19 1
20 2
21 2
22 2
23 3
27 1
29 1
31 1
32 1
35 1
38 1
Total   2,292
Frequency of Abdomen and Pelvis Symptoms
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Figure 6 Frequency of Visits by Women for Each Symptom (Digestive) 
  
Visits Women
0 1739 *****************************************************
1 316 **********
2 117 ****
3 46 *
4 36 *
5 7
6 9
7 4
8 4
9 3 24% of women had digestive symptoms
10 1
12 2
13 2
14 1
16 1
19 1
20 1
21 1
41 1
Total 2292
Frequency of Digestive Symptoms
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Figure 7 Frequency of Visits by Women for Each Symptom (Bladder) 
  
Visits Women
0 1885 *****************************************************
1 269 ********
2 71 **
3 28 *
4 17
5 8
6 3 18% of women had bladder symptoms
7 3
8 1
9 1
11 2
12 1
14 1
18 2
Total 2292
Frequency of Bladder Symptoms
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Figure 8 Frequency of Visits by Women for Each Symptom (Pain) 
  
Visits Women
0 1,261 *****************************************************
1 589 *************************
2 226 *********
3 100 ****
4 44 **
5 23 *
6 14 *
7 14 * 45% of women had pain symptoms
8 5
9 4
10 3
11 1 ` 
12 2
17 1
22 1
23 2
31 2
Total 2,292
Frequency of Pain Symptoms
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Figure 9  Combination of Symptoms Experienced By Visits & Age 
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Table 2 Combination of Symptoms Experienced By Visits & Age 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Symptom 
Combination 
by Age 20 30 40 50 60 65
Grand 
Total
% by 
Symptom
AbP+B 0 11 20 32 22 20 105 9%
AbP+B+D 0 2 5 9 7 7 30 2%
AbP+B+D+P 0 5 12 17 9 14 57 5%
AbP+D 2 8 47 53 44 54 208 17%
D+B 0 1 2 6 2 3 14 1%
P+AbP 24 92 112 166 46 62 502 41% *
P+AbP+B 5 13 37 33 14 17 119 10%
P+AbP+D 3 29 41 44 14 25 156 13%
P+B 1 4 4 5 3 8 25 2%
P+D 1 0 3 7 2 1 14 1%
Grand Total 36 165 283 372 163 211 1230 100%
% 3% 13% 23% 30% 13% 17% 100%
Age Group
Legend:
AbP+B Abdomen and Pelvis + Bladder
AbP+B+D
AbP+B+D+P
AbP+D
D+B
P+AbP
P+AbP+B
P+AbP+D
P+B
P+D
Pain + Abdomen and Pelvis + Digestive
Pain + Abdomen and Pelvis
Digestive + Bladder
Pain + Abdomen and Pelvis + Bladder
Abdomen and Pelvis + Bladder + Digestive + Pain
Abdomen and Pelvis + Bladder + Digestive
Abdomen and Pelvis + Digestive 
Pain + Bladder
Pain + Digestive
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Abstract Text: 
 
Background:  Over 60% of ovarian cancer cases are found at Stage III and IV. The 
US healthcare system does not support a standard screening method for ovarian 
cancer.  The purpose of this study is to determine whether certain types of symptoms 
are distinguishable between women diagnosed with ovarian cancer and women 
without cancer.  Methods:    Women diagnosed with ovarian cancer were randomly 
matched 1:1 to women without cancer to support a nested case-control analysis of 
health insurance claims between 2008 through 2013 from a commercial payer.  The 
following eligibility criteria was applied:  1) 24 years of age or older; 2) continuously 
enrolled in healthcare plan for a minimum period of 6 months;  3) experienced more 
than 1 symptom over the observation period; 4) an observation period of a minimum 
of 6 months; and 5) a Texas resident.  Symptoms were based on 47 ICD-9 diagnosis 
codes and categorized specific to pain, abdominal and pelvis, digestive, and bladder.  
A total of 1,578 women (789 cases; 789 controls) supported the analysis. Results:  
Sixty percent (60%) of women with ovarian cancer experienced the majority of 
associated pre-diagnosed symptoms analyzed for the study.  Visits occurred over a 
period of 6 months to 70 months.  Overall, ninety percent (90%; n=1,421) of the 
symptoms were experienced in abdomen and pelvis, with women with ovarian cancer 
visiting their physician for this complaint at 92% (n=725); OR of 1.66 (CI 1.14 to 2.41; 
P=.008).  Pain was reported as a complaint by cases at nearly 60% (n=464) and 
controls at 48% (n=376); OR of 1.75 (CI 1.39 to 2.19; P<.001).   Symptoms for bladder 
and digestive combined represented 68% of complaints for both cases (n=507) and 
controls (n=555), with results supporting no statistical significance to women 
diagnosed with ovarian cancer. Of the 1,578 women, 77% (cases=621; controls=595) 
experienced more than one type of symptom.  Both cases (n=206) and controls 
(n=153) complained of both abdomen and pelvis along with pain; OR of 1.54 (CI 1.19 
to 1.99; P=.001). A second combination including abdomen and pelvis with pain and 
digestive was experienced in 14% of women (cases n=99; controls n=67); OR 1.58; 
CI 1.13 to 2.22; P=.008.  Conclusions:   Certain recurring symptoms associated with 
abdomen and pelvis as well as pain appear to have indication of exposure to ovarian 
cancer, signifying that symptom awareness remains relevant to this disease that is 
diagnosed at a late stage and currently does not have routine screening methods to 
support early detection.   
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INTRODUCTION 
According to the Centers for Disease Control and Prevention (CDC), average 
life expectancy for women in the US has risen from 70 years old in 1980 to 80.1 in 
2015.  Preventive healthcare screenings and innovative therapies are contributing to 
longer survival.  This is evident in certain cancers, such as breast and lung, where the 
United States Preventative Services Task Force (USPSTF) recommends annual 
mammograms and low-dose CT scans to detect signs of breast or lung cancer, 
respectively.  Early detection along with choices in therapies have offered women the 
ability to go into remission for many years.   This is not the case, however, for ovarian 
cancer, which accounts for 4% of all cancers in women1.  Worldwide, over 200,000 
women are diagnosed with this disease and 125,000 die on an annual basis2.  In the 
U.S., the National Cancer Institute estimates that over 22,240 new cases occur 
annually and 14,070 women die from this cancer3.  Nearly 50% of the diagnosed cases 
occur in women under the age of 65 and overall survival is generally less than 5 
years4.  The survival rate is highly dependent on whether the cancer has spread to 
other organs, the woman’s age, race, and response to treatment4.   
Standard screening requirements to evaluate the potential risk are not 
supported by professional organizations such as The American Congress of 
Obstetricians and Gynecologists or the United States Preventative Services Task 
Force.  In 2018, The Journal of American Medical Association published USPSTF’s 
position that screenings for ovarian cancer in asymptomatic women with a blood test, 
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known as the cancer antigen 125 (CA-125), or transvaginal ultrasound are not 
beneficial, cost effective, and do not provide opportunities for an early diagnosis5.  The 
USPSTF has taken this position as a result of recent research that showed that these 
screening methods are inconsistent, leading to false positives or unremarkable 
findings.  This was corroborated by the National Cancer Institute’s Prostate, Lung, 
Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial, 
where nearly 80,000 women were randomized to either obtain annual screening tests 
using both the CA-125 and the transvaginal ultrasound or proceed with usual care.  
For women randomized to annual ovarian cancer screening methods, more than 
25,000 women were screened utilizing both tests in the first three years of the study, 
and then subsequently with CA-125 for a period of two years.  In total, 6 annual CA-
125 tests and 4 annual transvaginal ultrasounds were performed on each women 
involved in the study6.  The investigators of the PLCO study followed the women for 
over 12 years and determined there was no statistically significant reduction in 
mortality in ovarian cancer between the women that were tested annually versus 
women who received usual care6.   
While clinical research in ovarian cancer is occurring, it remains a challenge to 
direct an effective treatment that leads to long-term survival.  The inability to diagnose 
at an early stage and inadequate therapies are two primary reasons this disease is 
extremely difficult to diagnose or, subsequently, cure. Nearly 85% of women will be 
diagnosed when the cancer has spread or metastasized outside of the ovary, which 
leads to a premature death3.  
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The primary objective of this research is to continue to draw awareness to this 
disease and to assess whether certain symptoms are able to predict signs of ovarian 
cancer.   Symptom related research has been monitored in this disease for several 
decades.  In the 1970s, a study of over 5,000 women showed that most patients with 
ovarian cancer experienced symptoms anywhere from two weeks to ten years prior to 
diagnosis7. Other more recent research revealed that common targeted symptoms are 
evident between six and twenty-four months prior to diagnosis utilizing an ovarian 
cancer symptom index8,9. The index measures whether women experienced certain 
symptoms specific to pelvic/abdominal pain, difficulty eating, urinary urgency, and 
bloating prior to diagnosis. 
In general, ovarian cancer is perceived as having no disease specific 
symptoms8.  Women have a tendency to ignore common symptoms and attribute them 
to ageing, weight gain or other natural physiological processes10. This lack of 
recognition contributes to a delay in seeking medical attention10 and subsequently to 
a late presentation where the disease has metastasized within the lower abdomen11.  
Continuing to perform research to assess if symptoms in this disease are prevalent 
remains critical for both women as well as clinicians.  Evidence-based symptomology 
of this disease may, at a minimum, provide earlier detection.   
This study is a nested case-control analysis of healthcare claims from a large 
U.S. commercial payer.  The primary aim of this research is to assess whether certain 
symptoms are distinguishable between women diagnosed with ovarian cancer and 
women who did not develop cancer.  The research will explore a relationship between 
47 
 
the types of symptoms experienced as well as the frequency of recurring symptoms 
in women with ovarian cancer in comparison to women with no history of cancer.   
MATERIALS AND METHODS 
 This study was approved by the Institutional Review Board of The University of 
Texas – School of Public Health.   
Database Description 
The data and analysis for this case-control study was based on health claims 
data from a large U.S. commercial payer that provides health care coverage to over 
100 million people.  The insurance database and related medical claims were able to 
support demographic eligibility and study criteria.    
Case‐Control Study Design 
The rationale for this study is to evaluate how associated symptoms compare 
between women with ovarian cancer (case) to women with no history of cancer 
(control).  The analysis supported visits that occurred between January 1, 2008 
through December 31, 2013.  Symptoms were identified in both case and control 
groups by reported claims identified by 47 International Classification of Disease (ICD-
9) codes specific to pain, abdominal and pelvis, digestive, and bladder (Table 1).  All 
related symptoms were categorized and analyzed within one of the four symptom 
groups.  Specific to ovarian cancer cases, a review of symptoms prior to diagnosis 
only occurred.   Any claims that occurred subsequent to the diagnosis date were 
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dropped from the analysis.  Symptom visits for controls occurred over the continuous 
enrollment period.   
The women diagnosed with ovarian cancer (case group) comprised of an initial 
cohort of 4,406 from 3,596,696 unique women.  Inclusion criteria for the analysis were 
based on the following: a) women diagnosed with ovarian cancer (ICD-9 diagnosis 
codes: 183, malignant neoplasm of ovary, and 233.39, carcinoma in situ of the ovary); 
b) Texas resident; c) a minimum of 6 months of continuous enrollment in the plan; e) 
equal to or greater than 24 years of age at diagnosis; and f) experienced a related 
symptom documented by a specific ICD-9 code.  Of the 4,406 women diagnosed with 
ovarian cancer, 2,308 were dropped due to enrollment periods occurring either prior 
to January 1, 2008 or subsequent to December 31, 2013, symptoms were identified 
either on or subsequent to diagnosis date, did not meet the six-month minimum 
continuous enrollment period prior to diagnosis, did not have an consecutive 
observation period of a minimum of 180 days, or experience a minimum of two 
symptoms over the course of the observation period.  An additional 1,309 were 
dropped as no related symptoms were reported prior to diagnosis.  This resulted in 
789 women diagnosed with ovarian cancer to be matched 1:1 with women with no 
history of claims associated with cancer.   
 The control cohort was extracted from the claims database based on the same 
criteria as the cases with the exception of a cancer diagnosis.  Women with history of 
any type of cancer based on the International Classification of Disease (ICD-9) codes 
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140.x through 239.x were exempt from the control group.   This resulted in 317,748 
controls.    
The match was randomly based on the following criteria of each of the 789 
cases:  a) age at first symptom; b) first symptom experienced; and c) observation 
period.  If a control duplicated to a case based on criteria, a subsequent control with 
the same criteria was selected.  At complete dataset of 1578 (789 cases/789 controls) 
was created for the analysis.  A pair identifier was created to associate a case to 
control based on the match criteria.  This group variable along with a dependent 
variable supporting women with ovarian cancer (case) or without cancer (control) was 
applied to the conditional logistic regression when determining the association of 
symptoms between cases and controls.        
This research reports descriptive analyses as well as estimates of odds ratios 
(OR) with 95% confidence intervals (95%, CI) and statistical significance for the 
following:  i) comparison of type of symptoms in cases and controls, ii) comparison of 
combination of symptoms experienced, and iii) a summary of visits and observation 
periods in each category of symptoms specific to cases and controls.  The statistical 
package used for the analysis was STATA 13.1. 
RESULTS  
 The total number of women included in the analysis that met the study criteria 
and matched was 1,578 (case: 789 / control: 789).  Women ranged in age from 24 to 
86, with an average age of 51 (SD 12.3065).  Four hundred and eighty six women 
(n=486/1578; 31%) between the age of 50 and 59 represented the largest group of 
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women in the case control cohort. The analysis further revealed that 54% of women 
had a first symptom primarily presented with a complaint associated with abdomen 
and pelvis.  The second most frequent complaint was associated with pain (17%), 
followed by digestive (15%) and bladder (14%).  The observation period ranged from 
6 months to 70 months.  (Table 2).  
Women in both cases and controls experienced multiple symptoms throughout 
the respective observation period.  Both individual and combination of symptoms were 
constructed and analyzed based on the four primary symptom categories of abdomen 
and pelvis, bladder, digestive and pain.  Women in both groups (n=1578) could 
experience multiple visits associated with one symptom or across multiple symptoms.  
Overall, ninety percent (90%; n=1,421) of the symptoms were experienced in 
abdomen and pelvis, with women with ovarian cancer visiting their physician for this 
complaint at 92% (n=725) and women without cancer at 88% (n=696) (Table 3).  This 
particular group of symptoms produced an OR of 1.66 (CI 1.14 to 2.41; P=.008), 
indicating that recurring symptoms of abdomen and pelvis may be a predictive 
indicator of ovarian cancer compared to women without cancer.  Following abdomen 
and pelvis were symptoms associated with pain at 53% (n=840).  Cases (59%; n=464) 
had reported nearly 10% more complaints than controls (48%; n= 376).  Results for 
pain appear to also show an association to risk of ovarian cancer with an OR of 1.75 
(CI 1.39 to 2.19; P<.001).   Symptoms for bladder and digestive combined represented 
approximately 68% of complaints for both cases (n=507) and controls (n=555).  These 
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latter symptoms did not support they were predictive symptoms to the diagnosis of 
ovarian cancer with an odds ratio of .72 and .87, respectively (Table 3).      
Of the 1,578 women, 77% (cases=621; controls=595) experienced more than 
one type of symptom.   In reviewing ten combinations of symptoms, 30% experienced 
symptoms associated with pain along with abdomen and pelvis, and 17% experienced 
digestive with abdomen and pelvis (Table 4).  Odds ratios and related confidence 
intervals support that a certain combination of symptoms experienced in women prior 
to diagnosis may be discernable in comparison to women without cancer.  Compared 
to the analysis of the individual symptoms, 33% (n= 206) of women with ovarian 
cancer and 30% (n=153) of women without cancer complained of both abdomen and 
pelvis along with pain.  The OR produced a result of 1.54 (P=.001) revealing that the 
odds of symptom complaints for women with ovarian cancer to women without cancer 
were significant, possibly demonstrating an associated risk to the disease. This also 
applied to symptoms which, again, include abdomen and pelvis, along with pain, and 
digestive (OR 1.58; CI 1.13 to 2.22; P=.008).   
Total number of symptom visits reported within the respective observation 
months were evaluated in both cases and controls for each category of symptoms.  
The number of total visits equaled 13,126, with cases experiencing 60% (n=7890) of 
the visits. The average number of visits for controls equaled 6.63 (SD 5.27) and 10 for 
cases (SD 7.79). The average age of women experiencing symptoms during the 40 
months of observation ranged between 49 and 53.  Visits occurred over an 
observation period between six months to seventy months.  The analysis of each of 
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the category (digestive, bladder, pain and abdomen and pelvis) of symptoms showed 
that women with ovarian cancer had an average of more symptom visits per woman 
(Figures 1 through 4).  Additionally, a review of symptoms occurred between 6 months 
to 40 months (3.33 years), which demonstrated that over 70% of symptoms during 
this period occurred prior to diagnosis on 80% of the women with ovarian cancer.  
Comparatively, women diagnosed with ovarian cancer appear to experience, on 
average, an increase of number of visits associated with all symptoms than women 
without cancer.   
DISCUSSION  
Ovarian cancer continues to be recognized as a disease where long-term 
survival statistics are dismal.  Currently, the female gender comprises nearly 50% of 
the world population and life expectancy is expected to grow as a result of public 
health advances, which in turn is also projected to lead to an increase of cancer cases 
of nearly 10 million with 5.5 million deaths by 203012.   Agencies such as the National 
Cancer Institute, American Cancer Society, and other noteworthy coalitions assert that 
50% of ovarian cancer cases occur under the age of 65, with the median age of 63. 
The primary objective of this research was to determine a correlation of symptoms 
experienced in women diagnosed with ovarian cancer to women who do not develop 
cancer through a nested case control analysis.  The results of the research found that 
women diagnosed with ovarian cancer experienced 20% more symptom visits in 
comparison to women without cancer and the association was statistically significant 
in complaints associated with abdomen and pelvis along with pain.   
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The investigators recognize that this type of prescreening assessment cannot 
independently lead to a diagnosis of ovarian cancer.  However, this study does 
strongly suggest that a taxonomy of symptoms remains beneficial as a prescreening 
approach prior to pursuing tests, such as a CA125 or transvaginal, which can be 
expensive and also lead to false positives13.  Evaluation of symptoms in combination 
with a thorough risk assessment could lead to opportunities for better clinical decisions 
as well as offer earlier interventions.    Additionally, while not part of this research, it 
would be of interest to possibly reevaluate a portion of the controls on this study who 
experienced recurring symptoms and assess if a diagnosis of ovarian cancer was 
eventually determined.  The majority of women in this study were fifty and over which 
links to when the highest rates of diagnosis occur for this disease.     
Limitations and Strengths  
Insurance claims were historically developed for the purpose to support 
physician documentation and charge reimbursement, which for purposes of research, 
such as the one presented, has limitations.  For example, for this study, detailed 
clinical information about the disease, demographics, and stage of the disease are not 
captured in the claims data.  Additionally, the claims associated with this study are 
from a commercial payer, which eliminates any data from women who may be on 
primary healthcare plans associated with the Centers for Medicare and Medicaid 
Services.  This limits extrapolation of our findings to other populations such as 
uninsured and lower income women as well as women over the age of 65.   An 
additional limitation is that certain symptoms are subjective. For example, the 
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researchers recognize that pain was restricted to five (5) ICD-9 codes – dyspareunia, 
pelvic congestion syndrome, other to female genital organs, unspecified to female 
genital organs, and backache.  The five types of symptom complaints were included 
based on prior research related to the symptomology of ovarian cancer.  Future 
research in this area may need to expand the symptoms of pain and better define the 
type of pain experienced in order to better understand the association to ovarian 
cancer.   
 Apart from the limitations of the analysis, this research exhibits strengths.  The 
database used for this study has over 3.5 million women members in the state of 
Texas, and enabled the investigators to analyze age, time of symptoms to diagnosis, 
number of visits specific to related symptoms, as well as combination of symptoms 
without recall bias.  Another advantage of using claims data is the ability to evaluate 
visits across multiple providers. 
CONCLUSIONS 
Patients routinely experiencing a type of symptom epidemiology want to be 
referred and diagnosed expeditiously14.  While meaningful advancements continue to 
rapidly evolve in diagnostics, genetic testing, and therapies, ovarian cancer still 
remains without any type of standard screening method along with limited treatment 
options.  As with many cancer diagnoses, the assumption is that the earlier the 
disease is detected, the chances for long-term survival increase.  Educating women 
and health care providers about related symptoms needs to be part of the diagnostic 
strategy to increase early detection15.  This was recognized in the United Kingdom 
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Collaborative Trial of Ovarian Cancer Screening trial.  Although the outcome was not 
statistically significant,  the study did reveal a 15% reduction in ovarian cancer 
mortality with multimodal screening which includes a CA125 – based risk of ovarian 
cancer algorithm (known as ROCA) followed by transvaginal ultrasound, if the ROCA 
was abnormal16. 
In the United States, the National Cancer Institute is disclosing some early 
results of a NCI-funded study of an experimental pap screening test.  The 
retrospective study detected endometrial and ovarian cancer through DNA collected 
from blood and tissue3. Further research needs to continue, both within the U.S. and 
globally, to not only validate the efficacy of symptoms related to ovarian cancer, but 
also whether recurring symptoms are red flags to subsequently promote diagnostic 
testing through traditional methods (i.e. CA-125 blood test, transvaginal ultrasound) 
or more advanced methods such as molecular pathways evaluating the cytology of 
the human cells. A recent prospective study conducted at the Seattle Cancer Care 
Alliance and the University of Washington incorporated both a symptom assessment 
and a biomarker marker test to predict ovarian cancer in women with adnexal mass17.  
Women were initially interviewed prior to surgery regarding their symptoms.  
Symptoms that were shown to recur greater than 12 times in a one month period and 
were present for less than one year would be considered eligible to participate in the 
biomarker collection17.  The results of the study determined that incorporating both 
methods was effective in determining the risk of the disease and has the potential to 
improve patient outcomes.   
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The intent of this research is not to cause alarm, but to continue the awareness 
of symptoms associated of ovarian cancer and direct recurring symptoms of this 
disease into an integrative screening method that will lead to earlier referrals to 
gynecologic oncologists, that in turn, provide earlier diagnosis, which is considered 
essential in a disease that has dismal outcomes.  
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Table 1: Symptoms Categorized by ICD9 Diagnosis Codes (47 codes) 
 
Category  ICD9  Description                 Pain  6250  Dyspareunia                      
   6255  Pelvic congestion syndrome                   
   6258  Other specified symptoms associated with female genital organs       
   6259  Unspecified specified symptoms associated with female genital organs       
   7245  Backache                      
Abdomen & 
Pelvis  5340  Gastritis                          
   5781  Blood in stool                      
   6262  Excessive or frequent menstruation                
   6266  Metrorrhagia; bleeding unrelated to menstrual cycle; irregular intermenstrual bleeding 
   6267  Postcoital bleeding; bleeding from vagina after sexual intercourse       
   6268  Dysfunctional or functional uterine hemorrhage              
   6269  Disorders of menstruation & other abnormal bleeding from female genital tract; unspecified 
   7890  Abdominal pain                      
   78900  Abdominal pain; unspecified                   
   78901  Abdominal pain; right upper quadrant                
   78902  Abdominal pain; left upper quadrant                
   78903  Abdominal pain; right lower quadrant                
   78904  Abdominal pain; left lower quadrant                
   78905  Abdominal pain; periumbilic                   
   78906  Abdominal pain; epigastric                   
   78907  Abdominal pain; generalized                   
   78909  Abdominal pain; other specified site                
   7893  Abdominal or pelvic swelling, mass or lump             
   78930  Abdominal or pelvic swelling, mass or lump; unspecified          
   78935  Abdominal or pelvic swelling, mass or lump; periumbilic          
   78936  Abdominal or pelvic swelling, mass or lump; epigastric          
   78959  Ascites ‐ fluid in peritoneal cavity; other specified site          
   7896  Abdominal tenderness                   
   78965  Abdominal tenderness; periumbilic                
               
   78966  Abdominal tenderness; epigastric                
   78960  Abdominal tenderness; unspecified                
   7899  Other symptoms involving abdomen and pelvis             
Digestive  5361  Acute dilatation of stomach                   
   5369  Unspecified functional disorder of stomach             
   7830  Anorexia (loss of appetite)                   
   7831  Abnormal weight gain                   
   7832  Abnormal weight loss                   
   7873  Flatulence, eructation & gas pain                
   7879  Other symptoms involving digestive system             
   78791  Diarrhea                         
Bladder  7880  Renal colic                      
   7881  Dysuria                         
   7883  Urinary incontinence                   
   78840  Frequency of urination & polyuria                
   78841  Urinary frequency                      
   78842  Polyuria                         
   78843  Nocturia                         
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Table 2: Summary of Match Criteria  
 
  
Match Criteria for case controls
case( n=789) / 
control (n=789) %
Age at first symptom (years)
20‐29 50 3%
30‐39 230 15%
40‐49 414 26%
50‐59 486 31%
60‐69 186 12%
>65 212 13%
Total 1578 100%
First Symptom
abdom_pelvis 858 54%
bladder 226 14%
digestive 232 15%
pain 262 17%
Total 1578 100%
Observation Months
6‐12 mo. 414 26%
12‐24 mo. 520 33%
25‐36 mo. 332 21%
37‐48 mo. 156 10%
49‐60 mo. 122 8%
61‐70 mo. 34 2%
Total 1578 100%
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Table 3:  Individual symptoms experienced in women with ovarian cancer 
(case) and women without cancer (controls)   
 
 
 
Table 4:  Combination symptoms experienced in women with ovarian cancer 
(case) and women without cancer (controls)   
  
 
 
 
 
 
 
 
Combination Visits
case 
(n=789) % Case
control 
(n=789)
% 
Control
Total 
Visits
% 
Total Odds ratio (95% CI) P Value
AbP+B 55 9% 73 12% 128 11% .72 (.49 to 1.04) 0.09
AbP+B+D 22 4% 40 7% 62 5% .53 (.31 to .90) 0.20
AbP+B+D+P 45 7% 34 6% 79 6% 1.37 (.85 to 2.19) 0.19
AbP+D 89 14% 120 20% 209 17% .66 (.48 to .92) 0.01
D+B 13 2% 12 2% 25 2% 1.08 (.5 to 2.37) 0.84
P+AbP 206 33% 153 26% 359 30% 1.54 (1.19 to 1.99) 0.001
P+AbP+B 73 12% 63 11% 136 11% 1.85 (.83 to 1.70) 0.36
P+AbP+D 99 16% 67 11% 166 14% 1.58 (1.13 to 2.22) 0.008
P+B 10 2% 22 4% 32 3% .40 (.18 to .91) 0.028
P+D 9 1% 11 2% 20 2% .78 (.289 to 2.09) 0.62
Total Women Experiencing 
Combination of Symptoms 621 100% 595 100% 1,216 100%
Symptom 
case 
(n=789) % Case
control 
(n=789)
% 
Control
Total 
Women
% 
Total Odds ratio (95% CI) P Value
Digestive 281 36% 297 38% 578 37% .87 (.676 to 1.13) 0.298
Bladder 226 29% 258 33% 484 31% .72 (.54 to .96) 0.024
Pain 464 59% 376 48% 840 53% 1.75 (1.39 to 2.19) <.001
Abdom_Pelvis 725 92% 696 88% 1421 90% 1.66 (1.14 to 2.41) 0.008
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Figures 1 – 4: Frequency of Symptom Visits in women with ovarian cancer 
(cases) and women without cancer (controls) 
 
 
Figure 1 – Summary of Digestive Visits  
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Figure 2 – Summary of Bladder Visits 
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Figure 3 – Summary of Pain Visits 
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Figure 4 – Summary of Abdomen - Pelvis Visits 
 
 
 
 
